Ilaris
(canakinumab)Phase 3Monoclonal antibody
NovartisCanakinumab is used to treat certain inflammatory conditions, including gout attacks and rare autoinflammatory diseases where the body's immune system causes excessive inflammation. It works by blocking a protein in the body that triggers inflammation.[1] Ilaris is currently being investigated across 60 indications[3], with its most advanced program in Phase 3.[1]
Ilaris is one of 1118 small molecule programs targeting Pyoderma Gangrenosum. It is currently in Phase 3.
60
Indications
80
Total Trials
11
Active Trials
1,117
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 59 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Ilaris
NovartisPhase 3
Adriamycin
GGynecologic Oncology Group
Preclinical
Lexiscan
AstellasPreclinical
Lupron
EEastern Cooperative Oncology Group
Preclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Chirocaine
PPurdue Pharma LP
Preclinical
Acupan
YYonsei University
Preclinical
Aquasol E
NNational Eye Institute (NEI)
Preclinical
Vit D
PPost Graduate Institute of Medical Education and Research, Chandigarh
Preclinical
Dextromethorphan Hydrobromide
Boehringer IngelheimPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Efficacy and Safety6 trials
Systemic Juvenile Idiopathic Arthritis4 trials
Show 1 more trial
Rheumatoid Arthritis3 trials
Non-Small Cell Lung Cancer3 trials
51 more indications
Arthritis2 trials
Schnitzler syndrome2 trials
Ilaris® Effects in Schnitzler Syndrome (ILESCH)
Completed·—·Phase 2·NCT01390350·20 enrolled
Lung Cancer2 trials
Osteoarthritis2 trials
Pneumonia2 trials
Type 2 Diabetes2 trials
Familial Mediterranean Fever2 trials
COVID-192 trials
Cardiovascular2 trials
Pharyngitis1 trial
Cardioversion1 trial
Vasculitis1 trial
Ilaris® in Urticarial Vasculitis - Investigation of Treatment Responses
Completed·—·Phase 2·NCT01170936·10 enrolled
Type 2 Diabetic Patients1 trial
Chronic Obstructive Pulmonary Disease1 trial
Intravenous Administration1 trial
Treatment1 trial
Cognitive impairment1 trial
Renal Cell Carcinoma1 trial
A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma
Active, not recruiting·—·Phase 1·NCT04028245·17 enrolled
Metastatic NSCLC1 trial
Refractory1 trial
Type 1 Diabetes1 trial
Canakinumab Study in Individuals With Newly Diagnosed Type 1 Diabetes
Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT00947427·71 enrolled
MDS1 trial
Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA
Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT04798339·13 enrolled
Peripheral Artery Disease1 trial
Duchenne Muscular Dystrophy1 trial
Single Escalating Dose Pilot Trial of Canakinumab (ILARIS®) in Duchenne Muscular Dystrophy
Unknown status·—·Phase 1/2·NCT03936894·3 enrolled
Colchicine1 trial
Impaired glucose tolerance1 trial
Vascular Inflammation1 trial
Periodic Fever Syndrome1 trial
Proliferative Diabetic Retinopathy1 trial
Adult-Onset Still's Disease1 trial
Canakinumab for Treatment of Adult-onset Still's Disease
Terminated·—·Phase 2·NCT02204293·36 enrolled
Adjuvant Treatment1 trial
Prevention1 trial
Breast Cancer1 trial
Efficacy1 trial
Juvenile Idiopathic Arthritis1 trial
Hospitalized Patients1 trial
Contact Dermatitis1 trial
Pancreatic Cancer1 trial
Rheumatic Disease1 trial
Cigarette Smoking-Related Carcinoma1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[4]
Jun 17, 2009
ILARIS
BLA BLA125319
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for canakinumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]